AKT1 and hepatocellular carcinoma: However, there are still some limitations in this study, the use of activator and inhibitor on the PI3K/AKT pathway was lacked in in vivo experiment, thus additional studies are required to further delineate the mechanistic actions of formononetin on HCC.